​

AstraZeneca (AZN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AZN Stock Forecast

AstraZeneca (AZN) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $88.00, with a high of $88.00 and a low of $88.00. This represents a 31.25% increase from the last price of $67.05.

$60 $66 $72 $78 $84 $90 High: $88 Avg: $88 Low: $88 Last Closed Price: $67.05

AZN Stock Rating

AstraZeneca stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (51.35%), 14 Hold (37.84%), 4 Sell (10.81%), and 0 Strong Sell (0.00%).

Buy
Total 37 0 4 14 19 Strong Sell Sell Hold Buy Strong Buy

AZN Price Target Upside V Benchmarks

TypeNameUpside
StockAstraZeneca31.25%
SectorHealthcare Stocks 33.91%
IndustryDrug Manufacturers - General Stocks37.84%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$86.00
Last Closing Price$67.05$67.05$67.05
Upside/Downside--28.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25362--11
Mar, 25462--12
Feb, 25461--11
Jan, 25461--11
Dec, 24461--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024Etzer DaroutBMO Capital$88.00$81.198.39%31.25%
Sep 11, 2024Etzer DaroutBMO Capital$89.00$79.9411.33%32.74%
May 30, 2024John EadeArgus Research$85.00$76.8410.62%26.77%
May 28, 2024Etzer DaroutBMO Capital$82.00$76.746.85%22.30%
Jul 12, 2023Andrew BerensLeerink Partners$79.00$64.8621.80%17.82%
Jan 05, 2023BMO Capital$82.00$69.5017.99%22.30%
Nov 11, 2022Leerink Partners$78.00$65.0919.83%16.33%
May 04, 2022Leerink Partners$75.00$67.1711.66%11.86%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024BMO CapitalOutperformOutperformhold
Sep 13, 2024Deutsche BankSellHolddowngrade
Sep 12, 2024Deutsche BankHoldSelldowngrade
Sep 11, 2024BMO CapitalOutperformOutperformhold
Sep 11, 2024NordeaSelldowngrade
Aug 12, 2024Cowen & Co.BuyBuyhold
Jul 10, 2024BarclaysOverweightOverweighthold
Jul 02, 2024JefferiesHoldHoldhold
May 30, 2024Goldman SachsBuyinitialise
May 28, 2024BMO CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.22$0.04$1.06------
Avg Forecast$2.09$2.59$3.36$3.67$4.11$4.63$5.15$5.70$6.10
High Forecast$2.16$2.68$3.47$3.80$4.26$5.25$5.69$6.42$6.34
Low Forecast$2.01$2.49$3.16$3.58$4.05$4.40$4.57$5.25$5.85
Surprise %-41.63%-98.46%-68.45%------

Revenue Forecast

$25B $34B $43B $52B $61B $70B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$26.62B$37.42B$44.35B$45.81B-----
Avg Forecast$26.38B$36.41B$44.44B$45.81B$53.22B$56.79B$60.50B$64.28B$67.65B
High Forecast$27.02B$37.30B$45.54B$45.98B$53.59B$57.53B$60.61B$64.51B$69.72B
Low Forecast$25.56B$35.28B$42.41B$45.67B$52.69B$55.85B$60.39B$64.05B$65.51B
Surprise %0.91%2.76%-0.20%-0.00%-----

Net Income Forecast

$-5B $1B $7B $13B $19B $25B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.20B$112.00M$3.29B$5.96B-----
Avg Forecast$3.19B$-238.15M$-1.38B$5.96B$12.99B$15.08B$16.02B$18.22B$19.05B
High Forecast$3.83B$595.60M$-689.41M$8.94B$13.32B$16.40B$17.78B$20.04B$19.81B
Low Forecast$2.55B$-1.07B$-2.08B$2.97B$12.66B$13.76B$14.27B$16.40B$18.26B
Surprise %0.13%-147.03%-337.84%------

AZN Forecast FAQ

Is AstraZeneca stock a buy?

AstraZeneca stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 14 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that AstraZeneca is a favorable investment for most analysts.

What is AstraZeneca's price target?

AstraZeneca's price target, set by 37 Wall Street analysts, averages $88 over the next 12 months. The price target range spans from $88 at the low end to $88 at the high end, suggesting a potential 31.25% change from the previous closing price of $67.05.

How does AstraZeneca stock forecast compare to its benchmarks?

AstraZeneca's stock forecast shows a 31.25% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the drug manufacturers - general stocks industry (37.84%).

What is the breakdown of analyst ratings for AstraZeneca over the past three months?

  • April 2025: 27.27% Strong Buy, 54.55% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 36.36% Strong Buy, 54.55% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.

What is AstraZeneca’s EPS forecast?

AstraZeneca's average annual EPS forecast for its fiscal year ending in December 2024 is $4.11, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $4.63 in 2025, $5.15 in 2026, $5.7 in 2027, and $6.1 in 2028.

What is AstraZeneca’s revenue forecast?

AstraZeneca's average annual revenue forecast for its fiscal year ending in December 2024 is $53.22B, reflecting a 16.18% increase from the reported $45.81B in 2023. The forecast for 2025 is $56.79B, followed by $60.5B for 2026, $64.28B for 2027, and $67.65B for 2028.

What is AstraZeneca’s net income forecast?

AstraZeneca's net income forecast for the fiscal year ending in December 2024 stands at $12.99B, representing an 118.12% increase from the reported $5.96B in 2023. Projections indicate $15.08B in 2025, $16.02B in 2026, $18.22B in 2027, and $19.05B in 2028.